Brief: Diamyd Medical Receives Patent Protection In U.S, Japan For Remygen
06/02/2023 12:40
Feb 6 (Reuters) - Diamyd Medical AB DMYDb.ST :
* DIAMYD MEDICAL RECEIVES PATENT PROTECTION IN THE US AND
JAPAN
FOR GABA FORMULATION REMYGEN®
* US PATENT AND TRADEMARK OFFICE (USPTO) AND JAPANESE PATENT
OFFICE HAVE INFORMED DIAMYD MEDICAL THAT THEY WILL GRANT PATENT
FOR COMPANY'S ORAL FORMULATION OF GABA-BASED STUDY DRUG REMYGEN
* REMYGEN(®) IS CURRENTLY IN PHASE 2 DEVELOPMENT THROUGH
REGENERATE-1 TRIAL IN INDIVIDUALS WITH LONG-TERM TYPE 1 DIABETES
* RESULTS ARE EXPECTED LATER THIS QUARTER.
Source text for Eikon: ID:nWkr48mzrK
Further company coverage: DMYDb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))